Ticagrelor increases plasma adenosine concentration in patients after percutaneous coronary intervention
10.3969/j.issn.1004-8812.2017.03.006
- VernacularTitle:替格瑞洛升高经皮冠状动脉介入治疗术后患者血浆腺苷浓度的临床研究
- Author:
Yongchao MU
;
Xiaofei WANG
;
Lin CAI
- Keywords:
Ticagrelor;
Clopidogrel;
Percutaneous coronary intervention;
Adenosine
- From:
Chinese Journal of Interventional Cardiology
2017;25(3):149-152
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate and compare the plasma concentrations of adenosine in patients taking ticagrelor versus clopidogrel after percutaneous coronary intervention (PCI) and its influence on occurrence of adverse clinical events.Methods The study enrolled 180 patients who had received PCI in the Tianjin First Center Hospital between June 2014 to July 2016.The patients were divided into 2 groups as the ticagrelor group (n=90, patients given ticagrelor 90 mg twice daily) and the clopidogrel group (n=90, patients given clopidogrel 75 mg daily).The plasma concentration of adenosine was taken at 30 days and 90 days after PCI.The adenosine levels and clinical events were compared between the 2 groups.Results The adenosine concentration were higher in the ticagrelor group both at 30 days [(1.65±0.16) μmol/L vs.(0.71±0.08) μmol/L, P<0.01] and 90 days [(1.65±0.14) μmol/L vs.(0.72±0.06) μmol/L, P<0.01] than in the clopidogrel group.The rates of major adverse cardiocerebral events were lower in the ticagrelor group both at 30 days (3.3% vs.13.3%, P<0.05) and at 90 days (6.7% vs.15.6%, P<0.05) than in the clopidogrel group.No significant difference in bleeding complication between the 2 groups.Conclusions Ticagrelor increases the concentration of adenosine in patients after PCI which may have beneficial effect on reduction of clinical adverse events.
